Education
About Us
Working with TipRanks
Follow Us
LivaNova PLC (LIVN)
NASDAQ:LIVN
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.76Last Year’s EPS
0.73Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 25, 2025
|% Change Since: -25.21%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance with significant growth in key segments and positive clinical milestones. However, challenges in the epilepsy segment and uncertainties regarding SNIA litigation and tax rate increases were noted.Company Guidance
During LivaNova's earnings call, the company provided guidance for 2025, highlighting expected revenue growth between 5% and 6% on a constant-currency basis and between 6% and 7% on an organic basis. They anticipate a foreign currency headwind of 1.5% to 2%. For the cardiopulmonary segment, LivaNova forecasts revenue growth of 7% to 8%, driven by the expanded capacity and new market launches for the Essenz heart-lung machine. In the epilepsy segment, they expect global revenue to grow by 4% to 5%, with a mid-single-digit growth rate for U.S. new patient implants. The company also projects an adjusted effective tax rate of approximately 24% and adjusted diluted earnings per share in the range of $3.65 to $3.75. Adjusted free cash flow is expected to be between $135 million and $155 million, accounting for increased capital spending, particularly in IT infrastructure and cardiopulmonary capacity expansion.Strong Organic Revenue Growth
LivaNova delivered 11% organic revenue growth in 2024, marking the second consecutive year of double-digit organic growth.
Clinical Milestones Achievement
Clinical milestones achieved in obstructive sleep apnea, difficult-to-treat depression, and VNS therapy for epilepsy, including the successful OSPREY clinical study.
Cardiopulmonary Segment Performance
Cardiopulmonary revenue was $182 million in Q4, up 11% versus Q4 2023. Full-year cardiopulmonary revenue grew 14% to $684 million.
Adjusted Operating Income Growth
Achieved 41% growth in adjusted operating income and 21% growth in adjusted diluted earnings per share.
Free Cash Flow Improvement
Delivered $163 million in adjusted free cash flow for 2024, representing a 70% increase from the prior year.
Innovation and Product Development
Continued progress in innovation pipeline with new product launches like ProtekDuo Plus and focus on enhancing epilepsy and cardiopulmonary portfolios.
---
LIVN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LIVN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 25, 2025 | $49.50 | $41.70 | -15.76% |
| Oct 30, 2024 | $52.97 | $51.34 | -3.08% |
| Jul 31, 2024 | $51.30 | $49.40 | -3.70% |
| May 01, 2024 | $55.75 | $62.62 | +12.32% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does LivaNova PLC (LIVN) report earnings?
LivaNova PLC (LIVN) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is LivaNova PLC (LIVN) earnings time?
LivaNova PLC (LIVN) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LIVN EPS forecast?
LIVN EPS forecast for the fiscal quarter 2025 (Q1) is 0.76.
---